Five months after giving up on its lead drug Betalutin for follicular lymphoma, Nordic Nanovector has charted a course forward via a merger with fellow Norwegian biotech APIM Therapeutics.

Instead, myself and my siblings were embarrassed that there were no flowers from us at the service. I would avoid this site at ALL COSTS. Couldn't be more disappointed. Terrible, terrible service.

The biggest stories of the day delivered to your inbox.